{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:21:31Z","timestamp":1791354091389,"version":"4.3.1"},"publisher-location":"New York, NY","reference-count":115,"publisher":"Springer US","isbn-type":[{"value":"9781071633458","type":"print"},{"value":"9781071633465","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-3346-5_17","type":"book-chapter","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T12:01:45Z","timestamp":1689336105000},"page":"247-262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Value of Cell-Free Circulating DNA Profiling in Patients with Skin Diseases"],"prefix":"10.1007","author":[{"given":"Jingwen","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Youming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"issue":"4","key":"17_CR1","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabi\u00e8res","year":"2021","unstructured":"Alix-Panabi\u00e8res C, Pantel K (2021) Liquid biopsy: from discovery to clinical application [J]. Cancer Discov 11(4):858\u2013873","journal-title":"Cancer Discov"},{"issue":"5","key":"17_CR2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1001\/jamaoncol.2020.0346","volume":"6","author":"KS Shohdy","year":"2020","unstructured":"Shohdy KS, West HJ (2020) Circulating tumor DNA testing\u2014liquid biopsy of a cancer [J]. JAMA Oncol 6(5):792\u2013792","journal-title":"JAMA Oncol"},{"issue":"6","key":"17_CR3","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1470-2045(19)30310-9","volume":"20","author":"K Page","year":"2019","unstructured":"Page K, Shaw JA, Guttery DS (2019) The liquid biopsy: towards standardisation in preparation for prime time [J]. Lancet Oncology 20(6):758\u2013760","journal-title":"Lancet Oncology"},{"issue":"7800","key":"17_CR4","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1038\/d41586-020-00844-5","volume":"579","author":"C Alix-Panabieres","year":"2020","unstructured":"Alix-Panabieres C (2020) The future of liquid biopsy [J]. Nature 579(7800):S9\u2013S9","journal-title":"Nature"},{"issue":"6","key":"17_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/jama.2018.9418","volume":"320","author":"MA Allyse","year":"2018","unstructured":"Allyse MA, Wick MJ (2018) Noninvasive prenatal genetic screening using cell-free DNA [J]. JAMA 320(6):591\u2013592","journal-title":"JAMA"},{"key":"17_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-4939-8973-7_5","volume-title":"Cell-free DNA integrity: applications [M]\/\/cell-free DNA as diagnostic markers","author":"S Ravaioli","year":"2019","unstructured":"Ravaioli S (2019) Cell-free DNA integrity: applications [M]\/\/cell-free DNA as diagnostic markers. Humana Press, New York, pp 77\u201383"},{"issue":"9","key":"17_CR7","doi-asserted-by":"publisher","first-page":"200119","DOI":"10.1098\/rsob.200119","volume":"10","author":"A Zukowski","year":"2020","unstructured":"Zukowski A, Rao S, Ramachandran S (2020) Phenotypes from cell-free DNA [J]. Open Biol 10(9):200119","journal-title":"Open Biol"},{"issue":"33","key":"17_CR8","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1038\/s41388-021-01928-w","volume":"40","author":"S Liebs","year":"2021","unstructured":"Liebs S, Eder T, Klauschen F et al (2021) Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities [J]. Oncogene 40(33):5204\u20135212","journal-title":"Oncogene"},{"key":"17_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-3-030-26439-0_9","volume":"215","author":"N Papadopoulos","year":"2020","unstructured":"Papadopoulos N (2020) Pathophysiology of ctDNA release into the circulation and its characteristics: what is important for clinical applications [J]. Tumor Liquid Biopsies 215:163\u2013180","journal-title":"Tumor Liquid Biopsies"},{"issue":"3\u20134","key":"17_CR10","first-page":"241","volume":"142","author":"P MANDEL","year":"1948","unstructured":"MANDEL P, METAIS P (1948) Nuclear acids in human blood plasma. C R Seances Soc Biol Fil 142(3\u20134):241\u2013243","journal-title":"C R Seances Soc Biol Fil"},{"key":"17_CR11","first-page":"133","volume-title":"Circulating cell-free DNA in cancer [M]\/\/quantitative real-time PCR","author":"P Pinzani","year":"2014","unstructured":"Pinzani P, Salvianti F, Orlando C et al (2014) Circulating cell-free DNA in cancer [M]\/\/quantitative real-time PCR. Humana Press, New York, pp 133\u2013145"},{"issue":"12","key":"17_CR12","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.7150\/thno.45554","volume":"10","author":"D Han","year":"2020","unstructured":"Han D, Li R, Shi J et al (2020) Liquid biopsy for infectious diseases: a focus on microbial cell-free DNA sequencing [J]. Theranostics 10(12):5501","journal-title":"Theranostics"},{"issue":"2","key":"17_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/jpm11020151","volume":"11","author":"P Mondelo-Mac\u00eda","year":"2021","unstructured":"Mondelo-Mac\u00eda P, Castro-Santos P, Castillo-Garc\u00eda A et al (2021) Circulating free DNA and its emerging role in autoimmune diseases [J]. J Pers Med 11(2):151","journal-title":"J Pers Med"},{"key":"17_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cca.2018.01.007","volume":"479","author":"G Ponti","year":"2018","unstructured":"Ponti G, Maccaferri M, Manfredini M et al (2018) The value of fluorimetry (qubit) and spectrophotometry (NanoDrop) in the quantification of cell-free DNA (cfDNA) in malignant melanoma and prostate cancer patients [J]. Clin Chim Acta 479:14\u201319","journal-title":"Clin Chim Acta"},{"issue":"2","key":"17_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/jdv.16766","volume":"35","author":"R V\u00e1raljai","year":"2021","unstructured":"V\u00e1raljai R, Elouali S, Lueong SS et al (2021) The predictive and prognostic significance of cell-free DNA concentration in melanoma [J]. J Eur Acad Dermatol Venereol 35(2):387\u2013395","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"17_CR16","doi-asserted-by":"publisher","first-page":"102106","DOI":"10.1016\/j.ctrv.2020.102106","volume":"91","author":"M Cirillo","year":"2020","unstructured":"Cirillo M, Craig AFM, Borchmann S et al (2020) Liquid biopsy in lymphoma: molecular methods and clinical applications [J]. Cancer Treat Rev 91:102106","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"17_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PTC Wan","year":"2004","unstructured":"Wan PTC, Garnett MJ, Roe SM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF [J]. Cell 116(6):855\u2013867","journal-title":"Cell"},{"issue":"6892","key":"17_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer [J]. Nature 417(6892):949\u2013954","journal-title":"Nature"},{"issue":"4","key":"17_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/bjc.2013.29","volume":"108","author":"JS Wilmott","year":"2013","unstructured":"Wilmott JS, Menzies AM, Haydu LE et al (2013) BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma [J]. Br J Cancer 108(4):924\u2013931","journal-title":"Br J Cancer"},{"issue":"3","key":"17_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jmoldx.2013.12.004","volume":"16","author":"KL Aung","year":"2014","unstructured":"Aung KL, Donald E, Ellison G et al (2014) Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system [J]. J Mol Diagn 16(3):343\u2013349","journal-title":"J Mol Diagn"},{"issue":"3","key":"17_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","volume":"22","author":"A Santiago-Walker","year":"2016","unstructured":"Santiago-Walker A, Gagnon R, Mazumdar J et al (2016) Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical TrialsPrognostic value of BRAF mutation detection in circulation [J]. Clin Cancer Res 22(3):567\u2013574","journal-title":"Clin Cancer Res"},{"issue":"11","key":"17_CR22","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1515\/cclm-2019-0783","volume":"58","author":"E Tzanikou","year":"2020","unstructured":"Tzanikou E, Haselmann V, Markou A et al (2020) Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients [J]. Clin Chem Lab Med 58(11):1799\u20131807","journal-title":"Clin Chem Lab Med"},{"issue":"23\u201324","key":"17_CR23","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/j.cca.2011.07.027","volume":"412","author":"P Pinzani","year":"2011","unstructured":"Pinzani P, Salvianti F, Zaccara S et al (2011) Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations [J]. Clin Chim Acta 412(23\u201324):2141\u20132145","journal-title":"Clin Chim Acta"},{"issue":"1","key":"17_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/pcmr.12623","volume":"31","author":"TC Gangadhar","year":"2018","unstructured":"Gangadhar TC, Savitch SL, Yee SS et al (2018) Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma [J]. Pigment Cell Melanoma Res 31(1):73\u201381","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"17_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jdermsci.2021.04.006","volume":"102","author":"A Kaneko","year":"2021","unstructured":"Kaneko A, Kanemaru H, Kajihara I et al (2021) Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients [J]. J Dermatol Sci 102(3):158\u2013166","journal-title":"J Dermatol Sci"},{"issue":"7","key":"17_CR26","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/genes12071080","volume":"12","author":"M Olbryt","year":"2021","unstructured":"Olbryt M, Rajczykowski M, Bal W et al (2021) NGS analysis of liquid biopsy (LB) and formalin-fixed paraffin-embedded (FFPE) melanoma samples using Oncomine\u2122 Pan-cancer cell-free assay [J]. Genes 12(7):1080","journal-title":"Genes"},{"key":"17_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fmolb.2015.00076","volume":"2","author":"F Salvianti","year":"2016","unstructured":"Salvianti F, Orlando C, Massi D et al (2016) Tumor-related methylated cell-free DNA and circulating tumor cells in melanoma [J]. Front Mol Biosci 2:76","journal-title":"Front Mol Biosci"},{"issue":"6","key":"17_CR28","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/annonc\/mdy119","volume":"29","author":"L Liu","year":"2018","unstructured":"Liu L, Toung JM, Jassowicz AF et al (2018) Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification [J]. Ann Oncol 29(6):1445\u20131453","journal-title":"Ann Oncol"},{"issue":"11","key":"17_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049843","volume":"7","author":"F Salvianti","year":"2012","unstructured":"Salvianti F, Pinzani P, Verderio P et al (2012) Multiparametric analysis of cell-free DNA in melanoma patients [J]. PLoS One 7(11):e49843","journal-title":"PLoS One"},{"issue":"2","key":"17_CR30","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/cam4.61","volume":"2","author":"CHD Metz","year":"2013","unstructured":"Metz CHD, Scheulen M, Bornfeld N et al (2013) Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma [J]. Cancer Med 2(2):208\u2013215","journal-title":"Cancer Med"},{"issue":"1","key":"17_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-01984-w","volume":"40","author":"P Bustamante","year":"2021","unstructured":"Bustamante P, Tsering T, Coblentz J et al (2021) Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma [J]. J Exp Clin Cancer Res 40(1):1\u201316","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"17_CR32","first-page":"58","volume":"9","author":"JC Melms","year":"2018","unstructured":"Melms JC, Ho KW, Thummalapalli R et al (2018) Implementation of cell-free tumor DNA sequencing from the cerebrospinal fluid to guide treatment in a patient with primary leptomeningeal melanoma: a case report [J]. Mol Clin Oncol 9(1):58\u201361","journal-title":"Mol Clin Oncol"},{"issue":"51","key":"17_CR33","doi-asserted-by":"publisher","first-page":"85430","DOI":"10.18632\/oncotarget.13397","volume":"7","author":"P Momtaz","year":"2016","unstructured":"Momtaz P, Pentsova E, Abdel-Wahab O et al (2016) Quantification of tumor-derived cell free DNA (cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies [J]. Oncotarget 7(51):85430","journal-title":"Oncotarget"},{"issue":"1","key":"17_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/CMR.0000000000000786","volume":"32","author":"M Parietti","year":"2022","unstructured":"Parietti M, Marra E, Ribero S et al (2022) Leptomeningeal dissemination as a first sign of progression in metastatic melanoma: a diagnostic lesson [J]. Melanoma Res 32(1):55\u201358","journal-title":"Melanoma Res"},{"key":"17_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1200\/PO.20.00292","volume":"5","author":"SK Cheok","year":"2021","unstructured":"Cheok SK, Narayan A, Arnal-Estape A et al (2021) Tumor DNA mutations from intraparenchymal brain metastases are detectable in CSF [J]. JCO Precis Oncol 5:163\u2013172","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"17_CR36","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/cncy.22491","volume":"129","author":"ME Perrone","year":"2021","unstructured":"Perrone ME, Alvarez R, Vo TT et al (2021) Validating cell-free DNA from supernatant for molecular diagnostics on cytology specimens [J]. Cancer Cytopathol 129(12):956\u2013965","journal-title":"Cancer Cytopathol"},{"issue":"12","key":"17_CR37","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/1878-0261.12574","volume":"13","author":"S Villatoro","year":"2019","unstructured":"Villatoro S, Mayo-de-las-Casas C, Jordana-Ariza N et al (2019) Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions [J]. Mol Oncol 13(12):2633\u20132645","journal-title":"Mol Oncol"},{"key":"17_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.10.029","volume":"88","author":"S Valpione","year":"2018","unstructured":"Valpione S, Gremel G, Mundra P et al (2018) Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients [J]. Eur J Cancer 88:1\u20139","journal-title":"Eur J Cancer"},{"issue":"3","key":"17_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jdermsci.2020.01.001","volume":"97","author":"A Mikoshiba","year":"2020","unstructured":"Mikoshiba A, Ashida A, Sakaizawa K et al (2020) Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma [J]. J Dermatol Sci 97(3):172\u2013178","journal-title":"J Dermatol Sci"},{"issue":"9","key":"17_CR40","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1373\/clinchem.2018.290023","volume":"64","author":"S Silva","year":"2018","unstructured":"Silva S, Danson S, Teare D et al (2018) Genome-wide analysis of circulating cell-free DNA copy number detects active melanoma and predicts survival [J]. Clin Chem 64(9):1338\u20131346","journal-title":"Clin Chem"},{"issue":"6","key":"17_CR41","first-page":"1012","volume":"5","author":"JA Slostad","year":"2021","unstructured":"Slostad JA, Liu MC, Allred JB et al (2021) BRAF V600 mutation detection in plasma cell-free DNA: NCCTG N0879 (Alliance)[J]. Mayo Clin Proc 5(6):1012\u20131020","journal-title":"Mayo Clin Proc"},{"key":"17_CR42","first-page":"1","volume":"2","author":"SY Lin","year":"2018","unstructured":"Lin SY, Huang SK, Huynh KT et al (2018) Multiplex gene profiling of cell-free DNA in patients with metastatic melanoma for monitoring disease [J]. JCO Precis Oncol 2:1\u201330","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"17_CR43","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/CMR.0000000000000432","volume":"28","author":"M Gonzalez-Cao","year":"2018","unstructured":"Gonzalez-Cao M (2018) Mayo de las Casas C, Jordana Ariza N, et al. early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy [J]. Melanoma Res 28(3):195\u2013203","journal-title":"Melanoma Res"},{"issue":"10","key":"17_CR44","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/sj.bjc.6605371","volume":"101","author":"RE Board","year":"2009","unstructured":"Board RE, Ellison G, Orr MCM et al (2009) Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study [J]. Br J Cancer 101(10):1724\u20131730","journal-title":"Br J Cancer"},{"issue":"4","key":"17_CR45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/gtmb.2018.0193","volume":"23","author":"T Burjanivova","year":"2019","unstructured":"Burjanivova T, Malicherova B, Grendar M et al (2019) Detection of BRAFV600E mutation in melanoma patients by digital PCR of circulating DNA [J]. Genet Test Mol Biomarkers 23(4):241\u2013245","journal-title":"Genet Test Mol Biomarkers"},{"key":"17_CR46","doi-asserted-by":"crossref","unstructured":"Ashida A, Sakaizawa K, Uhara H, et al (2017) Circulating tumour DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients [D]. Shinshu University Library","DOI":"10.26226\/morressier.595a9c59d462b80296ca018f"},{"issue":"10","key":"17_CR47","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/annonc\/mdw278","volume":"27","author":"G Gremel","year":"2016","unstructured":"Gremel G, Lee RJ, Girotti MR et al (2016) Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA [J]. Ann Oncol 27(10):1959\u20131965","journal-title":"Ann Oncol"},{"issue":"3","key":"17_CR48","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0300891619900928","volume":"106","author":"K Kozak","year":"2020","unstructured":"Kozak K, Kowalik A, Gos A et al (2020) Cell-free DNA BRAF V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysis [J]. Tumori J 106(3):241\u2013248","journal-title":"Tumori J"},{"issue":"3","key":"17_CR49","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/lsm.23449","volume":"54","author":"S Palawisuth","year":"2022","unstructured":"Palawisuth S, Manuskiatti W, Apinuntham C et al (2022) Quantitative assessment of the long-term efficacy and safety of a 1064-nm picosecond laser with fractionated microlens array in the treatment of enlarged pores in Asians: a case-control study [J]. Lasers Surg Med 54(3):348\u2013354","journal-title":"Lasers Surg Med"},{"issue":"14","key":"17_CR50","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.3390\/cancers13143591","volume":"13","author":"P Rutkowski","year":"2021","unstructured":"Rutkowski P, Pauwels P, Kerger J et al (2021) Characterization and clinical utility of BRAF V600 mutation detection using cell-free DNA in patients with advanced melanoma [J]. Cancers 13(14):3591","journal-title":"Cancers"},{"issue":"26","key":"17_CR51","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","volume":"31","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Minor D, Ribas A et al (2013) Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma [J]. J Clin Oncol 31(26):3205\u20133211","journal-title":"J Clin Oncol"},{"issue":"1","key":"17_CR52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-016-2081-5","volume":"128","author":"Y Li","year":"2016","unstructured":"Li Y, Pan W, Connolly ID et al (2016) Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases [J]. J Neuro-Oncol 128(1):93\u2013100","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"17_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0653-6","volume":"7","author":"DP Hurkmans","year":"2019","unstructured":"Hurkmans DP, Verhoeven JGHP, de Leur K et al (2019) Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment [J]. J Immunother Cancer 7(1):1\u20137","journal-title":"J Immunother Cancer"},{"key":"17_CR54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clinbiochem.2018.10.002","volume":"63","author":"J Wu","year":"2019","unstructured":"Wu J, Tang W, Huang L et al (2019) The analysis of cell-free DNA concentrations and integrity in serum of initial and treated of lymphoma patients [J]. Clin Biochem 63:59\u201365","journal-title":"Clin Biochem"},{"issue":"1","key":"17_CR55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/annonc\/mdy476","volume":"30","author":"L Lenaerts","year":"2019","unstructured":"Lenaerts L, Vandenberghe P, Brison N et al (2019) Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors [J]. Ann Oncol 30(1):85\u201395","journal-title":"Ann Oncol"},{"issue":"2","key":"17_CR56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.canlet.2008.10.029","volume":"275","author":"G Hosny","year":"2009","unstructured":"Hosny G, Farahat N, Hainaut P (2009) TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin\u2019s lymphoma [J]. Cancer Lett 275(2):234\u2013239","journal-title":"Cancer Lett"},{"key":"17_CR57","doi-asserted-by":"publisher","first-page":"765544","DOI":"10.3389\/fonc.2021.765544","volume":"11","author":"H Fu","year":"2021","unstructured":"Fu H, Zhou H, Qiu Y et al (2021) SEPT6_TRIM33 gene fusion and mutated TP53 pathway associate with unfavorable prognosis in patients with B-cell lymphomas [J]. Front Oncol 11:765544\u2013765544","journal-title":"Front Oncol"},{"issue":"4","key":"17_CR58","doi-asserted-by":"publisher","first-page":"323","DOI":"10.7150\/jca.6226","volume":"4","author":"L Mussolin","year":"2013","unstructured":"Mussolin L, Burnelli R, Pillon M et al (2013) Plasma cell-free DNA in paediatric lymphomas [J]. J Cancer 4(4):323","journal-title":"J Cancer"},{"issue":"4","key":"17_CR59","doi-asserted-by":"publisher","first-page":"364","DOI":"10.7150\/jca.13593","volume":"7","author":"S Primerano","year":"2016","unstructured":"Primerano S, Burnelli R, Carraro E et al (2016) Kinetics of circulating plasma cell-free dna in paediatric classical Hodgkin lymphoma [J]. J Cancer 7(4):364","journal-title":"J Cancer"},{"key":"17_CR60","doi-asserted-by":"crossref","unstructured":"Bouzidi A, Labreche K, Baron M et al (2021) Low-coverage whole genome sequencing of cell-free DNA from immunosuppressed cancer patients enables tumor fraction determination and reveals relevant copy number alterations [J]. Front Cell Dev Biol 9:661272","DOI":"10.3389\/fcell.2021.661272"},{"issue":"2","key":"17_CR61","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1158\/1078-0432.CCR-20-2558","volume":"27","author":"A Rivas-Delgado","year":"2021","unstructured":"Rivas-Delgado A, Nadeu F, Enjuanes A et al (2021) Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study [J]. Clin Cancer Res 27(2):513\u2013521","journal-title":"Clin Cancer Res"},{"issue":"2","key":"17_CR62","doi-asserted-by":"publisher","first-page":"114","DOI":"10.5045\/br.2019.54.2.114","volume":"54","author":"M Eskandari","year":"2019","unstructured":"Eskandari M, Manoochehrabadi S, Pashaiefar H et al (2019) Clinical significance of cell-free DNA as a prognostic biomarker in patients with diffuse large B-cell lymphoma [J]. Blood Res 54(2):114\u2013119","journal-title":"Blood Res"},{"issue":"6","key":"17_CR63","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00277-020-04008-3","volume":"99","author":"JY Hur","year":"2020","unstructured":"Hur JY, Kim YJ, Yoon SE et al (2020) Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas [J]. Ann Hematol 99(6):1293\u20131302","journal-title":"Ann Hematol"},{"key":"17_CR64","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.blre.2020.100776","volume":"47","author":"G Regazzo","year":"2021","unstructured":"Regazzo G, Marchesi F, Spagnuolo M et al (2021) Diffuse large B-cell lymphoma: time to focus on circulating blood nucleic acids? [J]. Blood Rev 47:100776","journal-title":"Blood Rev"},{"key":"17_CR65","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.70520","volume":"10","author":"I Fox-Fisher","year":"2021","unstructured":"Fox-Fisher I, Piyanzin S, Ochana BL et al (2021) Remote immune processes revealed by immune-derived circulating cell-free DNA [J]. elife 10:e70520","journal-title":"elife"},{"issue":"19","key":"17_CR66","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1182\/bloodadvances.2019000175","volume":"3","author":"BCH Chiu","year":"2019","unstructured":"Chiu BCH, Zhang Z, You Q et al (2019) Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma [J]. Blood Adv 3(19):2790\u20132799","journal-title":"Blood Adv"},{"issue":"1","key":"17_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-020-00973-8","volume":"13","author":"HY Chen","year":"2021","unstructured":"Chen HY, Zhang WL, Zhang L et al (2021) 5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients [J]. Clin Epigenetics 13(1):1\u201314","journal-title":"Clin Epigenetics"},{"issue":"1","key":"17_CR68","doi-asserted-by":"publisher","first-page":"30. e1","DOI":"10.1016\/j.jtct.2021.10.007","volume":"28","author":"AM Goodman","year":"2022","unstructured":"Goodman AM, Holden KA, Jeong AR et al (2022) Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell Lymphomas [J]. Transplant Cell Ther 28(1):30. e1\u201330. e7","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"17_CR69","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","volume":"129","author":"D Rossi","year":"2017","unstructured":"Rossi D, Diop F, Spaccarotella E et al (2017) Diffuse large B-cell lymphoma genotyping on the liquid biopsy [J]. Blood 129(14):1947\u20131957","journal-title":"Blood"},{"key":"17_CR70","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.omtm.2021.10.009","volume":"23","author":"T Mika","year":"2021","unstructured":"Mika T, Thomson J, Nilius-Eliliwi V et al (2021) Quantification of cell-free DNA for the analysis of CD19-CAR-T cells during lymphoma treatment [J]. Mol Ther Methods Clin Dev 23:539\u2013550","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"17_CR71","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ajh.24751","volume":"92","author":"E Wedge","year":"2017","unstructured":"Wedge E, Hansen JW, Garde C et al (2017) Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma [J]. Am J Hematol 92(7):689\u2013694","journal-title":"Am J Hematol"},{"issue":"9","key":"17_CR72","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.3109\/10428194.2016.1139703","volume":"57","author":"V Camus","year":"2016","unstructured":"Camus V, Sarafan-Vasseur N, Bohers E et al (2016) Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma [J]. Leuk Lymphoma 57(9):2171\u20132179","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"17_CR73","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/ph14030207","volume":"14","author":"V Camus","year":"2021","unstructured":"Camus V, Jardin F (2021) Cell-free DNA for the management of classical Hodgkin Lymphoma [J]. Pharmaceuticals 14(3):207","journal-title":"Pharmaceuticals"},{"issue":"7","key":"17_CR74","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1182\/bloodadvances.2020003039","volume":"5","author":"L Buedts","year":"2021","unstructured":"Buedts L, Wlodarska I, Finalet-Ferreiro J et al (2021) The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA [J]. Blood Adv 5(7):1991\u20132002","journal-title":"Blood Adv"},{"issue":"6","key":"17_CR75","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1177\/1040638719880245","volume":"31","author":"M Tagawa","year":"2019","unstructured":"Tagawa M, Shimbo G, Inokuma H et al (2019) Quantification of plasma cell-free DNA levels in dogs with various tumors. J Vet Diagn Investig 31(6):836\u2013843","journal-title":"J Vet Diagn Investig"},{"key":"17_CR76","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3389\/fvets.2021.735682","volume":"8","author":"J Kim","year":"2021","unstructured":"Kim J, Bae H, Ahn S et al (2021) Cell-free DNA as a diagnostic and prognostic biomarker in dogs with tumors [J]. Front Vet Sci 8:1041","journal-title":"Front Vet Sci"},{"issue":"1","key":"17_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41525-021-00179-8","volume":"6","author":"BCH Chiu","year":"2021","unstructured":"Chiu BCH, Chen C, You Q et al (2021) Alterations of 5-hydroxymethylation in circulating cell-free DNA reflect molecular distinctions of subtypes of non-Hodgkin lymphoma [J]. NPJ Genom Med 6(1):1\u201310","journal-title":"NPJ Genom Med"},{"issue":"11","key":"17_CR78","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1182\/blood.2020007245","volume":"137","author":"K Shimada","year":"2021","unstructured":"Shimada K, Yoshida K, Suzuki Y et al (2021) Frequent genetic alterations in immune checkpoint\u2013related genes in intravascular large B-cell lymphoma [J]. Blood 137(11):1491\u20131502","journal-title":"Blood"},{"issue":"1","key":"17_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-020-00717-y","volume":"10","author":"P Decazes","year":"2020","unstructured":"Decazes P, Camus V, Bohers E et al (2020) Correlations between baseline 18F-FDG PET tumour parameters and circulating DNA in diffuse large B cell lymphoma and Hodgkin lymphoma [J]. EJNMMI Res 10(1):1\u201310","journal-title":"EJNMMI Res"},{"issue":"11","key":"17_CR80","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/bloodadvances.2019001075","volume":"4","author":"B Ottolini","year":"2020","unstructured":"Ottolini B, Nawaz N, Trethewey CS et al (2020) Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma [J]. Blood Adv 4(11):2392\u20132403","journal-title":"Blood Adv"},{"issue":"11","key":"17_CR81","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/bloodadvances.2020001637","volume":"5","author":"F Qi","year":"2021","unstructured":"Qi F, Cao Z, Chen B et al (2021) Liquid biopsy in extranodal NK\/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring [J]. Blood Adv 5(11):2505\u20132514","journal-title":"Blood Adv"},{"issue":"2","key":"17_CR82","doi-asserted-by":"publisher","first-page":"323","DOI":"10.7150\/jca.27615","volume":"10","author":"P Sun","year":"2019","unstructured":"Sun P, Chen C, Xia Y et al (2019) Mutation profiling of malignant lymphoma by next-generation sequencing of circulating cell-free DNA [J]. J Cancer 10(2):323","journal-title":"J Cancer"},{"issue":"10","key":"17_CR83","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1111\/cas.14176","volume":"110","author":"Y Suehara","year":"2019","unstructured":"Suehara Y, Sakata-Yanagimoto M, Hattori K et al (2019) Mutations found in cell-free DNA s of patients with malignant lymphoma at remission can derive from clonal hematopoiesis [J]. Cancer Sci 110(10):3375\u20133381","journal-title":"Cancer Sci"},{"issue":"18","key":"17_CR84","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2217\/pgs-2019-0099","volume":"20","author":"V Camus","year":"2019","unstructured":"Camus V, Jardin F (2019) Cell-free DNA and the monitoring of lymphoma treatment [J]. Pharmacogenomics 20(18):1271\u20131282","journal-title":"Pharmacogenomics"},{"key":"17_CR85","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/978-1-0716-0377-2_16","volume-title":"Liquid biopsy for investigation of cancer DNA in esophageal squamous cell carcinoma [M]\/\/esophageal squamous cell carcinoma","author":"RA Smith","year":"2020","unstructured":"Smith RA, Lam AK (2020) Liquid biopsy for investigation of cancer DNA in esophageal squamous cell carcinoma [M]\/\/esophageal squamous cell carcinoma. Humana, New York, NY, pp 203\u2013215"},{"issue":"5","key":"17_CR86","first-page":"733","volume":"16","author":"P Kumari","year":"2021","unstructured":"Kumari P, Syed SA, Wahid M et al (2021) Expression of miR-31 in saliva-liquid biopsy in patients with oral squamous cell carcinoma [J]. J Taibah Univ Med Sci 16(5):733","journal-title":"J Taibah Univ Med Sci"},{"key":"17_CR87","doi-asserted-by":"publisher","first-page":"104631","DOI":"10.1016\/j.oraloncology.2020.104631","volume":"104","author":"R Galot","year":"2020","unstructured":"Galot R, van Marcke C, Helaers R et al (2020) Liquid biopsy for mutational profiling of locoregional recurrent and\/or metastatic head and neck squamous cell carcinoma [J]. Oral Oncol 104:104631","journal-title":"Oral Oncol"},{"key":"17_CR88","doi-asserted-by":"publisher","unstructured":"Ng SP, Hall CS, Meas S et al (2020) Circulating tumour cell and cell-free DNA kinetics during radiotherapy in patients with intact head and neck squamous cell carcinoma [J]. medRxiv https:\/\/doi.org\/10.1101\/2020.10.13.20211516","DOI":"10.1101\/2020.10.13.20211516"},{"issue":"3","key":"17_CR89","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/bjd.17709","volume":"181","author":"T Mijiddorj","year":"2019","unstructured":"Mijiddorj T, Kajihara I, Tasaki Y et al (2019) Serum cell-free DNA levels are a useful marker for extramammary Paget disease [J]. Br J Dermatol 181(3):505\u2013511","journal-title":"Br J Dermatol"},{"issue":"3","key":"17_CR90","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/exd.14476","volume":"31","author":"S Sawamura","year":"2022","unstructured":"Sawamura S, Mijiddorj Myangat T, Kajihara I et al (2022) Genomic landscape of circulating tumour DNA in metastatic extramammary Paget\u2019s disease [J]. Exp Dermatol 31(3):341\u2013348","journal-title":"Exp Dermatol"},{"issue":"4","key":"17_CR91","first-page":"181","volume":"17","author":"JH Hughes","year":"1978","unstructured":"Hughes JH, Stoll DB (1978) Kaposi sarcoma. Am Fam Physician 17(4):181\u2013182","journal-title":"Am Fam Physician"},{"issue":"1","key":"17_CR92","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","volume":"5","author":"E Cesarman","year":"2019","unstructured":"Cesarman E, Damania B, Krown SE et al (2019) Kaposi sarcoma. Nat Rev Dis Primers 5(1):9","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"17_CR93","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/infdis\/jis032","volume":"205","author":"M Shamay","year":"2012","unstructured":"Shamay M, Hand N, Lemas MV et al (2012) CpG methylation as a tool to characterize cell-free Kaposi sarcoma herpesvirus DNA [J]. J Infect Dis 205(7):1095\u20131099","journal-title":"J Infect Dis"},{"issue":"9074","key":"17_CR94","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0140-6736(97)05257-4","volume":"350","author":"RS Stern","year":"1997","unstructured":"Stern RS (1997) Psoriasis. Lancet 350(9074):349\u2013353","journal-title":"Lancet"},{"key":"17_CR95","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","volume":"7","author":"GK Perera","year":"2012","unstructured":"Perera GK, Di Meglio P, Nestle FO (2012) Psoriasis. Annu Rev Pathol 7:385\u2013422","journal-title":"Annu Rev Pathol"},{"issue":"10","key":"17_CR96","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00403-017-1785-5","volume":"309","author":"M Beranek","year":"2017","unstructured":"Beranek M, Fiala Z, Kremlacek J et al (2017) Changes in circulating cell-free DNA and nucleosomes in patients with exacerbated psoriasis [J]. Arch Dermatol Res 309(10):815\u2013821","journal-title":"Arch Dermatol Res"},{"issue":"9","key":"17_CR97","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/1346-8138.15422","volume":"47","author":"R Sakamoto","year":"2020","unstructured":"Sakamoto R, Sawamura S, Kajihara I et al (2020) Circulating tumor necrosis factor-\u03b1 DNA are elevated in psoriasis [J]. J Dermatol 47(9):1037\u20131040","journal-title":"J Dermatol"},{"issue":"11","key":"17_CR98","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus [J]. Arthritis Rheum 25(11):1271\u20131277","journal-title":"Arthritis Rheum"},{"key":"17_CR99","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.molimm.2018.01.003","volume":"94","author":"C Zhang","year":"2018","unstructured":"Zhang C, Chen J, Cai L et al (2018) DNA induction of MDM2 promotes proliferation of human renal mesangial cells and alters peripheral B cells subsets in pediatric systemic lupus erythematosus [J]. Mol Immunol 94:166\u2013175","journal-title":"Mol Immunol"},{"issue":"11","key":"17_CR100","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00296-019-04426-1","volume":"39","author":"I Jeremic","year":"2019","unstructured":"Jeremic I, Djuric O, Nikolic M et al (2019) Neutrophil extracellular traps-associated markers are elevated in patients with systemic lupus erythematosus [J]. Rheumatol Int 39(11):1849\u20131857","journal-title":"Rheumatol Int"},{"issue":"1\u20132","key":"17_CR101","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cellimm.2014.08.002","volume":"292","author":"S Tug","year":"2014","unstructured":"Tug S, Helmig S, Menke J et al (2014) Correlation between cell free DNA levels and medical evaluation of disease progression in systemic lupus erythematosus patients [J]. Cell Immunol 292(1\u20132):32\u201339","journal-title":"Cell Immunol"},{"issue":"6","key":"17_CR102","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI. A disease activity index for lupus patients [J]. Arthritis Rheum 35(6):630\u2013640","journal-title":"Arthritis Rheum"},{"issue":"11","key":"17_CR103","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13015","volume":"48","author":"Y Xu","year":"2018","unstructured":"Xu Y, Song Y, Chang J et al (2018) High levels of circulating cell-free DNA are a biomarker of active SLE [J]. Eur J Clin Investig 48(11):e13015","journal-title":"Eur J Clin Investig"},{"key":"17_CR104","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaut.2016.06.006","volume":"74","author":"G Moroni","year":"2016","unstructured":"Moroni G, Depetri F, Ponticelli C (2016) Lupus nephritis: when and how often to biopsy and what does it mean? [J]. J Autoimmun 74:27\u201340","journal-title":"J Autoimmun"},{"issue":"13","key":"17_CR105","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1177\/0961203320957717","volume":"29","author":"A Truszewska","year":"2020","unstructured":"Truszewska A, Wirkowska A, Gala K et al (2020) Cell-free DNA profiling in patients with lupus nephritis [J]. Lupus 29(13):1759\u20131772","journal-title":"Lupus"},{"issue":"24","key":"17_CR106","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.2169\/internalmedicine.53.2570","volume":"53","author":"S Zhang","year":"2014","unstructured":"Zhang S, Lu X, Shu X et al (2014) Elevated plasma cfDNA may be associated with active lupus nephritis and partially attributed to abnormal regulation of neutrophil extracellular traps (NETs) in patients with systemic lupus erythematosus [J]. Intern Med 53(24):2763\u20132771","journal-title":"Intern Med"},{"issue":"5","key":"17_CR107","doi-asserted-by":"publisher","first-page":"e20201138","DOI":"10.1084\/jem.20201138","volume":"218","author":"J Hartl","year":"2021","unstructured":"Hartl J, Serpas L, Wang Y et al (2021) Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus [J]. J Exp Med 218(5):e20201138","journal-title":"J Exp Med"},{"issue":"8","key":"17_CR108","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1177\/09612033211010339","volume":"30","author":"A Truszewska","year":"2021","unstructured":"Truszewska A, Wirkowska A, Gala K et al (2021) EBV load is associated with cfDNA fragmentation and renal damage in SLE patients [J]. Lupus 30(8):1214\u20131225","journal-title":"Lupus"},{"issue":"8","key":"17_CR109","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.tig.2021.04.005","volume":"37","author":"DSC Han","year":"2021","unstructured":"Han DSC, Lo YMD (2021) The nexus of cfDNA and nuclease biology [J]. Trends Genet 37(8):758\u2013770","journal-title":"Trends Genet"},{"issue":"7","key":"17_CR110","first-page":"633","volume":"37","author":"J Huang","year":"2021","unstructured":"Huang J, Li Z, Cheng L et al (2021) Comparison of plasma levels and immunoactivities of different forms of circulating-free DNA in systemic lupus erythematosus patients [J]. Xi bao yu fen zi Mian yi xue za zhi = Chinese J Cell Mol Immunol 37(7):633\u2013640","journal-title":"Xi bao yu fen zi Mian yi xue za zhi = Chinese J Cell Mol Immunol"},{"issue":"5","key":"17_CR111","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0190-9622(81)80321-0","volume":"4","author":"BH Thiers","year":"1981","unstructured":"Thiers BH (1981) Pemphigus. J Am Acad Dermatol 4(5):603\u2013605","journal-title":"J Am Acad Dermatol"},{"issue":"10201","key":"17_CR112","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","volume":"394","author":"E Schmidt","year":"2019","unstructured":"Schmidt E, Kasperkiewicz M, Joly P (2019) Pemphigus Lancet 394(10201):882\u2013894. https:\/\/doi.org\/10.1016\/S0140-6736(19)31778-7","journal-title":"Pemphigus Lancet"},{"issue":"1","key":"17_CR113","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1111\/1346-8138.15620","volume":"48","author":"Y Kakitsuka","year":"2021","unstructured":"Kakitsuka Y, Sawamura S, Kajihara I et al (2021) Serum levels of desmoglein-1 DNA copies in cell-free DNA of patients with pemphigus [J]. J Dermatol 48(1):e31\u2013e32","journal-title":"J Dermatol"},{"issue":"62","key":"17_CR114","doi-asserted-by":"publisher","first-page":"105000","DOI":"10.18632\/oncotarget.21072","volume":"8","author":"P Momtaz","year":"2017","unstructured":"Momtaz P, Harding JJ, Ariyan C et al (2017) Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E\/K mutation [J]. Oncotarget 8(62):105000","journal-title":"Oncotarget"},{"issue":"1","key":"17_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-021-02401-3","volume":"22","author":"E Zozaya-Vald\u00e9s","year":"2021","unstructured":"Zozaya-Vald\u00e9s E, Wong SQ, Raleigh J et al (2021) Detection of cell-free microbial DNA using a contaminant-controlled analysis framework [J]. Genome Biol 22(1):1\u201322","journal-title":"Genome Biol"}],"container-title":["Methods in Molecular Biology","Liquid Biopsies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3346-5_17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T12:10:20Z","timestamp":1689336620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3346-5_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071633458","9781071633465"],"references-count":115,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3346-5_17","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"15 July 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}